Consequently, a rationale of the combinational use of both MIF and VEGF inhibitors in treating recurrent MPE in advanced NSCLC could be established, and further animal studies and clinical trials should be conducted to validate its efficacy and safety. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.